

Expression and Secretion of T-Cell Receptor $V\alpha$ and $V\beta$ Domains using *Escherichia coli* as a Host

E. S. WARD

Cancer Immunobiology Center and Department of Microbiology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA

Ward, ES. Expression and Secretion of T-Cell Receptor $V\alpha$ and $V\beta$ Domains using *Escherichia coli* as a Host. Scand J Immunol 1991;34: 215–20

An expression system for the production of recombinant T-cell receptor (TCR) variable domains would, *inter alia*, allow structural studies to be carried out and provide protein for the generation of anti-clonotypic antibodies. In this report the $V\alpha$ and $V\beta$ domain genes have been isolated from a T-cell hybridoma which is associated with the pathogenesis of experimental allergic encephalomyelitis (EAE) in the H-2^d mouse. These have been expressed as secreted domains in *Escherichia coli*, using secretion vectors previously used for the production of immunoglobulin fragments. Both $V\alpha$ and $V\beta$ domains are secreted in milligram quantities into the culture supernatant, although the levels of the $V\alpha$ domain are about 10–20 fold higher than those of the $V\beta$ domain. This expression system offers a rapid route for the production of recombinant TCRs in soluble form.

E. Sally Ward, Cancer Immunobiology Center and Department of Microbiology, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75235-8576, USA

The majority of T cells recognize antigenic peptides bound to class I or II proteins of the major histocompatibility complex (MHC) and are thus 'MHC restricted' [1]. The recognition of peptide-MHC complexes is mediated by surface-bound T-cell receptors (TCRs), which comprise heterodimeric $\alpha\beta$ glycoproteins [2–5] and constitute the vast majority of TCRs. A minority (1–10%) of T cells bear $\gamma\delta$ [6–8] or $\gamma\gamma$ [9] polypeptides whose function is less well characterized than that of the $\alpha\beta$ TCRs; a common feature of these three types of different TCRs is that they are associated with at least five components of the CD3 complex on the T-cell surface [10–12] to form TCR-CD3 complexes. TCR diversity is required for the recognition of an almost unlimited number of different peptide antigens associated with the highly polymorphic MHC molecules, and this diversity is achieved by somatic recombination of TCR V, (D), and J elements and extensive N-region addition (reviewed in Ref. 13). To date there is no evidence to suggest that somatic mutation contributes to TCR diversity.

A detailed understanding at the molecular level of the binding of TCRs to cognate peptide-MHC

complexes would greatly expand the existing knowledge for one of the key interactions of the immune system, and would for example assist in the development of immunotherapy for T-cell mediated autoimmune diseases. To date, structural studies such as X-ray crystallography or NMR have not been reported for TCRs. This is probably due to the problems which have been encountered in the expression of TCRs in suitable form and yield to allow such analyses. Several expression systems for the production of recombinant TCRs in mammalian cell transfectomas have been documented [14–17], but as yet expression of these proteins in a prokaryotic host has not been reported. The use of *E. coli* as a host is attractive, as a bacterial expression system offers a convenient and rapid route for TCR production.

Recently antibody Fv, Fab, and single VH domains have been expressed as secreted proteins in fully functional form in *E. coli* [18–21]. Molecular modelling has indicated that there are structural similarities between the immunoglobulin Fab fragment and the extracellular domains of TCRs [22, 23]. This suggests that it might be

possible to develop an *E. coli*-based expression system for TCRs which is analogous to that used for antibody fragments. Such a system would greatly facilitate structure-function studies of TCRs, in addition to providing an extremely useful source of TCR protein for immunization to generate anti-clonotypic antibodies.

In this report, the cloning and expression of the variable domains ($V\alpha$ and $V\beta$) of a pathogenic TCR in *E. coli* are described. The genes encoding the TCR $V\alpha$ and $V\beta$ domains of the T-cell hybridoma 1934.4 [24] have been isolated using the polymerase chain reaction (PCR, Ref. 25), and cloned into plasmid vectors designed for the expression and secretion of immunoglobulin domains [20]. These TCR genes have been selected for this study as the 1934.4 hybridoma is derived from a pathogenic CD4+ T-cell clone [26] which is associated with induction of experimental allergic (autoimmune) encephalomyelitis (EAE) in the H-2^a mouse. EAE is a prototypic model of T-cell mediated autoimmune disease, and is believed to be a valuable model for multiple sclerosis in humans [27]. Moreover, the binding specificity of the 1934.4 T-cell hybridoma has been extensively characterized [24]. Thus the expression of the 1934.4 TCR should allow studies to be carried out which may have important implications in both the mechanism and therapy of T-cell mediated autoimmune disease.

MATERIALS AND METHODS

Bacterial strains and plasmids. *E. coli* BMH71-18 [28] has been used as a host for the cloning and expression of TCR domains. The plasmid pSW1-VH-poly-tag1 has been previously described [20], except that pUC19 has been replaced by pUC119 [29] as the backbone vector.

Isolation of $V\alpha$ and $V\beta$ genes. The $V\alpha$ and $V\beta$ genes were isolated from 1934.4 hybridoma cells (a generous gift of Dr D. Wraith) using the PCR [25] and the following oligonucleotides (the 1934.4 TCR $V\alpha$ and $V\beta$ sequences have been described, Ref. 26):

$V\alpha$: I: 5' ATC CTT CCA TGG CCG ACT
CAG TGA CTC AGA CGG AAG GT 3'
II: 5' AAG GAT GGT GAC CGG TTT
AAT GGT GAG TTT GGT TCC 3'
 $V\beta$: III: 5' ATC CTT CCA TGG CCG AGG
CTG CAG TCA CCG AAA GTC CA 3'
IV: 5' AAG GAT GGT GAC CAG AAC
AGT CAG TCT GGT TCC TGA 3'

Note that for each domain, the oligonucleotides encode either an *Nco*I or *Bst*EII site (indicated by underlining) to allow restriction enzyme digestion of the PCR products, followed by gel purification (using United States Biochemical Corp. 'GeneClean') and ligation as

an *Nco*I-*Bst*EII fragment into VHNco-poly-tag1 (see below). For the isolation of genomic DNA from 1934.4 hybridoma cells, 5×10^5 cells were pelleted, washed once with phosphate buffered saline and resuspended in 500 μ l sterile distilled water. The cell suspension was then boiled for 5 min, and then centrifuged for 3 min at room temperature at 11,000 rpm [30]. Two to ten microlitres (2–10 μ l) of the supernatant was used in each PCR. PCR conditions were as follows: a typical reaction comprised 3 units Promega Taq polymerase, 5 μ l 10 \times Promega reaction buffer, 25 pmol of each oligonucleotide primer, 0.2 mM dNTPs, 2–10 μ l 1934.4 hybridoma supernatant, water to 50 μ l. Cycling conditions were 94°C (0.5 min), 55°C (0.5 min), 72°C (1 min), and Taq polymerase was added at the end of the first cycle i.e. at 72°C. Thirty cycles of the PCR were performed, and an additional 3 units of Taq polymerase were added after 15 cycles to minimize the occurrence of PCR errors.

Construction of plasmids for expression of TCR $V\alpha$ and $V\beta$ domains. pSW1-VH-poly-tag1 [20] has been modified by the insertion of a unique *Nco*I site into the pelB leader sequence using site-directed mutagenesis [31] and the oligonucleotide 5' GGC CAT GGC TGG TTG GG 3' to generate VHNco-poly-tag1. The genes, isolated and tailored by the PCR, were then cloned (in translational frame) as *Nco*I-*Bst*EII fragments into VHNco-poly-tag1 to generate $V\alpha$ pelBtag1 and $V\beta$ pelBtag1 (Fig. 1). To construct $V\alpha V\beta$ pelBtag1, $V\alpha$ pelBtag1 was modified by replacement of the 5' *Hind*III site of pUC119 [29] with an *Eco*RI site (by ligation of oligonucleotide V. 5' AGC TGA ATT C 3' as a duplex into *Hind*III restricted $V\alpha$ pelBtag1; the *Eco*RI site is shown underlined and the ligation destroys the *Hind*III site) and then cloned as an *Eco*RI fragment into *Eco*RI restricted $V\beta$ pelBtag1 (Fig. 1). Recombinants were then analysed for the correct orientation of the $V\alpha$ gene with respect to the $V\beta$ gene by restriction enzyme analysis. Dideoxynucleotide sequencing [32] was carried out to confirm the DNA sequences of the plasmid constructions shown in Fig. 1.

Expression analysis of $V\alpha$ and $V\beta$ domains. *E. coli* recombinants harbouring $V\alpha$ pelBtag1, $V\beta$ pelBtag1, and $V\alpha V\beta$ pelBtag1 were grown up in 2 \times TY plus 100 μ g/ml ampicillin and 1% (wt/vol) glucose to early stationary phase, pelleted by centrifugation, washed once in either 2 \times TY or 50 mM NaCl and then induced by resuspension in 2 \times TY plus 100 μ g/ml ampicillin and 1 mM isopropyl- β -D-thiogalactopyranoside (IPTG) for 14–16 h. Cultures were grown and induced at 37°C with shaking at 250 rpm. Culture supernatants were analysed by western blotting [33] as described [20], using the monoclonal antibody 9E10 [34] followed by anti-mouse Fc conjugated to horseradish peroxidase (ICN Immunobiologicals) for detection. Diaminobenzidine (Sigma, St Louis, MO, USA) was used as the horseradish peroxidase substrate.

RESULTS AND DISCUSSION

Expression of the single $V\alpha$ and $V\beta$ domains

The 1934.4 genes were cloned into VHNco-poly-tag1 to generate $V\alpha$ pelBtag1 ($V\alpha$ gene only)




FIG. 1. Construction of plasmids for expression of the $V\alpha$ domain ($V\alpha$ pelBtag1), $V\beta$ domain ($V\beta$ pelBtag1) and co-expression of the two domains ($V\alpha V\beta$ pelBtag1). H = *HindIII*, N = *NcoI*, B = *BstEII* and E = *EcoRI*. Oligonucleotide numbers are as in the Materials and Methods section. Filled in box = pelB leader, stippled box = $V\beta$ gene, striped box = five 3' codons of VH gene in pSW1-VH-poly-tag1 [20] plus tag1 (c-myc) codons [34], open box = $V\alpha$ gene and open circle = *lacZ* promoter [29].

and $V\beta$ pelBtag1 ($V\beta$ gene only) and transformed into *E. coli* BMH71-18 (Fig. 1). The nucleotide sequences of the constructions were confirmed by DNA sequencing prior to growing up and inducing *E. coli* recombinants for expression, as described in the Materials and Methods section. Culture supernatants were then analysed by western blotting (Fig. 2). The $V\alpha$ and $V\beta$ domains are expressed individually, which is a similar result to that observed for the expression and secretion of single immunoglobulin VH domains [20]. The molecular weights, from SDS gel analysis, are estimated to be 17 kDa ($V\alpha$ -tag1) and 14.5 kDa ($V\beta$ -tag1). For the $V\alpha$ domain this is significantly higher than that predicted by amino acid analysis, but in this respect anomalously low gel mobilities have been observed for single antibody VH domains (Ward, unpublished). Of interest is the particularly high level of secretion of the $V\alpha$ domain: the expression level of this domain is similar to, if not greater than, that observed for the immunoglobulin FvD1.3 fragment expressed and secreted in *E. coli* [20]. The level is estimated to be 10 mg per litre of culture, by comparison with culture supernatants of *E. coli* recombinants harbouring pSW1-VHD1.3- $V\kappa$ D1.3-tag1 [20] using western blotting. The

relatively high expression level of the $V\alpha$ domain may reflect a propensity of this domain to form homodimers, as an earlier report describes the expression of $V\alpha$ -immunoglobulin C κ chimaeras as homodimers in mammalian cells [15]. Such homodimer formation could mask the hydrophobic residues of the $V\alpha$ domain which, in a native TCR, interact with analogous $V\beta$ residues during $V\alpha$: $V\beta$ pairing, and this could increase the solubility (and secretion levels) of the homodimer. The oligomeric state of the secreted $V\alpha$ domains is currently being assessed.

In contrast to the $V\alpha$ domain, the $V\beta$ domain is secreted into the culture supernatant at levels which are similar to those observed for single immunoglobulin VH domains (about 0.5–1 mg per litre of culture, Ref. 20), despite the observation that the intracellular/periplasmic levels of the $V\beta$ domain are similar to those of the $V\alpha$ domain (data not shown). The reasons for the lower secretion levels of the $V\beta$ domain are currently unclear, but suggest that this protein does not fold into a soluble form as readily as the $V\alpha$ domain. Thus it may be possible to increase the amount of secreted $V\beta$ by altering the induction conditions. Alternatively, high levels of soluble $V\beta$ domain may be obtainable by osmotically




FIG. 2. Expression analysis of $V\alpha$ and $V\beta$ domains, by western blotting of culture supernatants electrophoresed on a 15% SDS polyacrylamide gel. *E. coli* recombinants harbouring the following plasmids were analysed: lane 1, $V\alpha V\beta$ pelBtag1; lane 2, $V\beta$ pelBtag1, and lane 3, $V\alpha$ pelBtag1. The mobilities of molecular weight size standards, run on an equivalent gel which was stained with Coomassie brilliant blue rather than transferred onto nitrocellulose, are indicated (in kDa) on the right margin.

shocking the recombinant *E. coli* cells, followed by denaturation and refolding of the released $V\beta$ protein.

Co-expression of $V\alpha$ and $V\beta$ domains

The $V\alpha$ and $V\beta$ domains can be co-expressed and secreted from *E. coli* recombinants harbouring $V\alpha V\beta$ pelBtag1 (Fig. 2). The $V\alpha$ polypeptide is secreted in excess over the $V\beta$ domain, suggesting that at least some of the recombinant TCR protein is not heterodimeric. Interestingly, however, the $V\alpha$ domain secretion levels are lower when co-expressed with the $V\beta$ polypeptide than when expressed and secreted as a single domain (compare lanes 1 and 3, Fig. 2). The possible

reasons for this are currently under investigation. This may be due, for example, to limitations on the amount of protein which can be secreted into the *E. coli* periplasm i.e. $V\beta$ secretion may compete with $V\alpha$ secretion. Alternatively, there may be some polarity effects on the expression of the $V\alpha$ domain, which is 3' to the $V\beta$ gene in $V\alpha V\beta$ pelBtag1 (Fig. 1).

In summary, the 1934.4 TCR $V\alpha$ and $V\beta$ polypeptides can be expressed and secreted from recombinant *E. coli* cells as either individual domains or co-expressed. This secretion system can be used as a rapid and economically favourable alternative to the existing methods for the production of TCRs or TCR-immunoglobulin chimaeras in mammalian cell transfectomas [14–17]. The yields of about 10 mg/l for $V\alpha$ and 0.5–1 mg/l for $V\beta$ can be readily scaled up to produce relatively large quantities of these TCR domains in a matter of days, using the peptide tag as an epitope for affinity purification with the 9E10 monoclonal antibody [34]. Thus the expression system could provide a valuable source of soluble TCR protein for use in immunizations for the generation of anti-clonotypic antibodies, which could be used for example in passive immunization for the treatment of disease. It is also conceivable that such soluble TCRs (derived from pathogenic T cells) could be used in vaccination to generate a specific anti-TCR response *in vivo* in a similar way to that reported using peptides derived from TCR V-regions [35–37]. Moreover, the recombinant $V\alpha$ or $V\beta$ domains, or even subfragments thereof, could be extremely useful for mapping the TCR residues which are functionally important in binding peptide-MHC complexes in murine EAE.

ACKNOWLEDGMENTS

I would like to thank Dr David Wraith for his collaboration and advice, Ms Jy Ping Tang for excellent technical assistance, and Dr Richard Baer for helpful discussion of the manuscript. I am grateful to the Department of Microbiology, Southwestern Medical Center for providing my start-up funds which have been used to support this work.

REFERENCES

- 1 Zinkernagel RM, Doherty PC. MHC-restricted

- cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T cell restriction specificity, function and responsiveness. *Adv Immunol* 1979;27:52-77.
- 2 Allison JP, MacIntyre BW, Block D. Tumor specific antigen of murine T-lymphoma defined with monoclonal antibody. *J Immunol* 1982;129:2293-300.
 - 3 Meuer SC, Fitzgerald KA, Hussey RE, Hodgdon JC, Schlossman SF, Reinherz EL. Clonotypic structures involved in antigen-specific human T cell function. Relationship to the T3 molecular complex. *J Exp Med* 1983;157:705-19.
 - 4 Haskins K, Kubo R, White J, Pigeon M, Kappler J, Marrack P. The major histocompatibility complex-restricted antigen receptor on T cells. I. Isolation with a monoclonal antibody. *J Exp Med* 1983; 157:1149-69.
 - 5 Samelson LE, Germain RN, Schwartz RH. Monoclonal antibodies against the antigen receptor on a cloned T-cell hybrid. *Proc Natl Acad Sci USA* 1983; 80:6972-6.
 - 6 Brenner MB, McLean J, Dialynas DP, Strominger JL, Smith JA, Owen FL, Seidman JG, Ip S, Rosen F, Krangel MS. Identification of a putative second T cell receptor. *Nature* 1986;322:145-9.
 - 7 Pardoll DM, Fowlkes BJ, Bluestone JA, Kruisbeek A, Maloy WL, Coligan JE, Schwartz RH. Differential expression of two distinct T cell receptors during thymocyte development. *Nature* 1987;326:79-81.
 - 8 Borst J, van de Griend RJ, van Oostveen JW, Ang SL, Melief CJ, Seidman JG, Bolhuis RLH. A T cell receptor γ /CD3 complex found on cloned functional lymphocytes. *Nature* 1987;325:683-8.
 - 9 Alarcon B, DeVries J, Pettey C, Boylston A, Yssel H, Terhorst C, Spits H. The T-cell receptor γ chain-CD3 complex: Implication in the cytotoxic activity of a CD3⁺ CD4⁻ CD8⁻ human natural killer clone. *Proc Natl Acad Sci USA* 1987;84:3861-5.
 - 10 Samelson LE, Harford JB, Klausner RD. Identification of the components of the murine T cell antigen receptor complex. *Cell* 1985;43:223-31.
 - 11 Oettgen HC, Pettey CL, Maloy WL, Terhorst C. A T3-like protein complex associated with the antigen receptor on murine T cells. *Nature* 1986;320:272-5.
 - 12 Berkhout B, Alarcon B, Terhorst C. Transfection of genes encoding the T cell receptor associated CD3 complex into COS cells results in assembly of the macromolecular structure. *J Biol Chem* 1988; 263:8528-36.
 - 13 Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. *Nature* 1988;334:395-402.
 - 14 Gascoigne NRJ, Goodnow CC, Dudzik KI, Oi VT, Davis MM. Secretion of a chimeric T-cell receptor-immunoglobulin protein. *Proc Natl Acad Sci USA* 1987;84:2936-40.
 - 15 Mariuzza RA, Winter G. Secretion of a homodimeric V α C κ T-cell receptor-immunoglobulin chimeric protein. *J Biol Chem* 1989;264:7310-16.
 - 16 Lin AY, Devaux B, Green A, Sagerström C, Elliott JF, Davis MM. Expression of T-cell antigen receptors in a lipid-linked form. *Science* 1990;249:677-9.
 - 17 Gascoigne NR. Transport and secretion of truncated T cell receptor β -chain occurs in the absence of association with CD3. *J Biol Chem* 1990;265:9296-301.
 - 18 Skerra A, Plückthun A. Assembly of a functional immunoglobulin Fv fragment in *Escherichia coli*. *Science* 1988;240:1038-41.
 - 19 Better M, Chang CP, Robinson RR, Horwitz AH. *Escherichia coli* secretion of an active chimeric antibody fragment. *Science* 1988;240:1041-3.
 - 20 Ward ES, Güssow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from *Escherichia coli*. *Nature* 1989;341:544-6.
 - 21 Huse WD, Sastry L, Iverson SA, Kang AS, Alting-Mees M, Burton DR, Benkovic SJ, Lerner RA. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. *Science* 1989;246:1275-81.
 - 22 Novotny J, Tonegawa S, Saito H, Kranz DM, Eisen HN. Secondary, tertiary, and quaternary structure of T-cell specific immunoglobulin-like polypeptide chains. *Proc Natl Acad Sci USA* 1986;83:742-6.
 - 23 Chothia C, Boswell DR, Lesk AM. The outline structure of the T-cell $\alpha\beta$ receptor. *EMBO J* 1988; 7:3745-55.
 - 24 Wraith DC, Smilek DE, Mitchell DJ, Steinman L, McDevitt HO. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. *Cell* 1989;59:247-55.
 - 25 Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. *Science* 1988; 239:487-91.
 - 26 Acha-Orbea H, Mitchell DJ, Timmerman L, Wraith DC, Tausch GS, Waldor MK, Zamvil SS, McDevitt HO, Steinman L. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. *Cell* 1988;54:263-73.
 - 27 Wisniewski HM, Keith AB. Chronic relapsing experimental encephalomyelitis; an experimental model of multiple sclerosis. *Ann Neurol* 1977; 1:144-8.
 - 28 Rütger U, Koenen M, Otto K, Müller-Hill B. pUR322, a vector for cloning and rapid chemical sequencing of DNA. *Nucleic Acids Res* 1981; 9:4087-98.
 - 29 Viera J, Messing J. In: Wu R, Grossman L, eds. *Methods in Enzymology*. London and New York: Academic Press Inc., 1987;153:3-11.
 - 30 Clackson T, Güssow D, Jones PT. General applications of PCR to gene cloning and manipulation. In: 'PCR: A Practical Approach', Oxford University Press, 1991, in press.
 - 31 Carter PJ, Bedouelle H, Winter G. Improved oligonucleotide site-directed mutagenesis using M13 vectors. *Nucleic Acids Res* 1985;13:4431-43.
 - 32 Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain terminating inhibitors. *Proc Natl Acad Sci USA*. 1977;74:5463-7.
 - 33 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to

T cell
receptor peptide therapy triggers autoregulation of
experimental
251;430-2.